Fig. 1
Hypoxia-dependent overexpression of MAP17 in HCC. a Venn diagram showed differentially expressed genes (DEGs) related to hypoxia and glycolysis in HCC; The Cancer Genome Atlas (TCGA) cohort (n = 369) was used for identifying glycolysis-related genes and hypoxia-related genes in HCC. b Immunohistochemical analysis of MAP17 protein expression in 202 matched HCC tissues and nontumor tissues; representative images of MAP17 staining were shown at the left panel; right panel showed the number of specimens displaying high or low MAP17 staining within the tumor or nontumor tissues (Fisher’s exact test, ***P < 0.001); scale bar: 50 μm. c Kaplan-Meier curve analysis for overall survival was performed according to MAP17 expression in HCC patients (n = 202); HR: hazard ratio. d Real-time qPCR and western blotting analysis of MAP17 expression in liver cancer cell lines. e-f SK-H929, MHCC-97H, and Huh7 cells were cultured under hypoxia (1% O2) and normoxia (20% O2) for 24 h, followed by detection of MAP17 mRNA expression by real-time qPCR (e, n = 3) and western blotting (f), respectively. g-h Under hypoxic culture condition (1% O2), MAP17 expression in MHCC-97H and Huh7 cells in the presence or absence of HIF1α knockdown was analyzed by real-time qPCR (G, n = 3) and western blotting (h), respectively. i Chromatin immunoprecipitation-PCR validation of the regulatory role of HIF-1α in MAP17 expression. Input and ChIP cycle threshold (Ct) values were normalized separately to control as 1. *P < 0.05; **P < 0.01; ***P < 0.001